*To the Editor*:

Five to twenty percent of hospitalized patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection are admitted to the ICU, with mortality reported between 26% and 61.5% ([@bib1]--[@bib3]). Nearly all ICU patients present with respiratory failure, and up to 88% are managed with invasive mechanical ventilation ([@bib1]--[@bib3]).

Descriptions of the pathophysiological characteristics of coronavirus disease (COVID-19) respiratory failure are limited. Reports of preserved respiratory system mechanics despite severe hypoxemia in early small series have led some investigators to hypothesize that a significant proportion of COVID-19 respiratory failure is not the typical acute respiratory distress syndrome (ARDS) and warrants alternative management ([@bib4], [@bib5]).

A detailed characterization of COVID-19 respiratory failure and its response to established ARDS therapies is needed before rigorous comparisons of established and new strategies can be contemplated. We describe the respiratory pathophysiology of patients with COVID-19 respiratory failure treated with invasive mechanical ventilation at two tertiary care hospitals in Boston, Massachusetts.

Methods
=======

Population and setting
----------------------

We studied all adult inpatients with SARS-CoV-2 infection and respiratory failure managed with invasive mechanical ventilation at Massachusetts General Hospital and Beth Israel Deaconess Medical Center between March 11 and March 30, 2020. The studies were granted exemption by the hospital institutional review boards. Informed consent was waived.

Clinical management occurred at the discretion of the treating physician. Hospital treatment guidelines recommended ventilation with V[t]{.smallcaps}s of \<6 ml/kg predicted body weight, early consideration of prone ventilation for Pa~O~2~~:F[i]{.smallcaps}~O~2~~ \< 200, and conservative fluid management. Positive end-expiratory pressure (PEEP) was titrated per institutional protocols and included use of the lower-PEEP/higher-F[i]{.smallcaps}~O~2~~ ARDS network table, titration by best tidal compliance, and esophageal manometry ([@bib6]). Both institutions recommended against the routine use of high-flow nasal cannula or noninvasive positive-pressure ventilation.

Data collection and definitions
-------------------------------

Data were collected from the electronic medical records. ARDS was defined according to the Berlin criteria ([@bib7]). We estimated the physiological dead-space fraction using the unadjusted Harris-Benedict estimate of resting energy expenditure and the rearranged Weir equation for CO~2~ production ([@bib8]). We calculated the ventilatory ratio as previously described ([@bib9]).

Statistical analysis
--------------------

We used descriptive statistics to summarize the clinical data. The results are reported as medians and interquartile ranges (IQRs). Categorical variables are reported as counts and percentages. We report all available data without imputation. We performed analyses with GraphPad Prism v7.0 software.

Results
=======

Demographic and clinical characteristics
----------------------------------------

From March 11 to March 30, 2020, 66 patients with laboratory-confirmed COVID-19 were intubated and admitted to ICUs at Massachusetts General Hospital and Beth Israel Deaconess Medical Center. The patients' demographics, clinical characteristics, therapies, and outcomes are summarized in [Table 1](#tbl1){ref-type="table"}. The median age was 58 years (range, 23--87 yr), and 43 patients (65%) were male. Eight patients (12%) had preexisting pulmonary disease, and 22 patients (34%) were current or former smokers.

###### 

Patient Characteristics and Laboratory Values on Hospital Presentation

  Characteristics                                                                                All Patients      
  ------------------------------------------------------------------------------------------ --------------------- -------
  Site                                                                                                                 
   Massachusetts General Hospital                                                                     73%           48/66
   Beth Israel Deaconess Medical Center                                                               27%           18/66
  Demographics                                                                                                         
   Age, yr, median (range)                                                                        58 (23--87)       66/66
   Sex, *n* (%)                                                                                                        
    Male                                                                                              65%           43/66
   Body mass index, median (IQR)                                                                  30 (27--35)       66/66
  Comorbidities                                                                                                        
   Pulmonary disease                                                                                  12%           8/66
   Current smoker or former smoker                                                                    34%           22/64
   Hypertension                                                                                       44%           29/66
   Diabetes mellitus                                                                                  26%           17/66
   Chronic kidney disease                                                                             6%            4/66
   Immunocompromise                                                                                   9%            6/66
   Malignancy                                                                                         8%            5/66
  Home medications                                                                                                     
   ACEi or ARB                                                                                        27%           18/66
   Statin                                                                                             34%           21/62
  Presentation                                                                                                         
   Symptom onset to admission, d, median (IQR)                                                     7 (6--10)        66/66
   Symptom onset to intubation, d, median (IQR)                                                    8 (6--10)        66/66
   Presenting symptoms                                                                                                 
    Fever                                                                                             86%           57/66
    Cough                                                                                             88%           58/66
    Dyspnea                                                                                           91%           60/66
    Congestion                                                                                        15%           10/65
    Nausea/vomiting                                                                                   22%           14/65
    Diarrhea                                                                                          28%           18/65
    Myalgias                                                                                          55%           36/66
    Fatigue                                                                                           67%           44/66
   Presenting laboratory values, median (IQR)                                                                          
    White blood cell count, 1,000/mm^3^                                                         7.6 (5.7--9.7)      65/66
    Lymphocyte count, 1,000/mm^3^                                                              0.93 (0.66--1.16)    65/66
    C-reactive protein, mg/L                                                                     159 (88--233)      57/66
    Ferritin, μg/L                                                                             923 (590--1,548)     52/66
    D-dimer, ng/ml                                                                            1,144 (789--2,440)    50/66
    Lactate dehydrogenase, IU/L                                                                 442 (351--584)      54/66
    Creatine kinase, U/L                                                                        210 (107--395)      42/66
    IL-6, pg/ml                                                                               126.7 (65.0--343.0)   46/66
  Respiratory parameters on intubation                                                                                 
   Bilateral infiltrates on chest X-ray                                                               97%           64/66
   Pa~O~2~~:F[i]{.smallcaps}~O~2~~, median (IQR)                                                182 (135--245)      65/66
   Estimated physiological dead-space fraction, median (IQR)                                   0.45 (0.38--0.58)    65/66
   Ventilatory ratio, median (IQR)                                                             1.25 (1.06--1.44)    65/66
   Ventilator parameters on intubation, median (IQR)                                                                   
    Positive end-expiratory pressure, cm H~2~O                                                    10 (8--12)        66/66
    Plateau pressure, cm H~2~O                                                                    21 (19--26)       48/66
    Driving pressure, cm H~2~O                                                                    11 (9--12)        48/66
    Static compliance, ml/cm H~2~O                                                                35 (30--43)       48/66
    Resistance, cm H~2~O/L/s                                                                       5 (4--7)         48/66
  ICU therapies                                                                                                        
   High-flow nasal cannula                                                                            2%            1/66
   Non-invasive positive pressure ventilation                                                         2%            1/66
   Invasive mechanical ventilation                                                                   100%           66/66
    Invasive mechanical ventilation, HD initiated, median (IQR)                                    1 (1--2)            
   Prone position                                                                                     47%           31/66
    Prone position, HD initiated, median (IQR)                                                     3 (2--5)            
   Neuromuscular blockade                                                                             42%           28/66
    Neuromuscular blockade, HD initiated, median (IQR)                                             2 (1--2)            
   Inhaled pulmonary vasodilator                                                                      27%           18/66
    Inhaled pulmonary vasodilator, HD initiated, median (IQR)                                      3 (1--3)            
   Extracorporeal membrane oxygenation                                                                5%            3/66
    Extracorporeal membrane oxygenation, HD initiated, median (range)                              2 (2--5)            
   Renal replacement therapy                                                                          20%           13/66
    Renal replacement therapy, HD initiated, median (IQR)                                          9 (5--13)           
   Vasopressors                                                                                       95%           63/66
  Selected inpatient medications                                                                                       
   Antibiotics                                                                                        98%           65/66
   Glucocorticoids                                                                                    8%            5/66
   Statins                                                                                            82%           54/66
   Hydroxychloroquine                                                                                 91%           60/66
   Azithromycin                                                                                       97%           64/66
   Remdesevir (or placebo)                                                                            26%           17/66
   Lopinavir/ritonavir                                                                                3%            2/66
   Anti--IL-6 antibody                                                                                11%           7/66
  Outcomes                                                                                                             
   Patient follow-up, d, median (range)                                                           34 (30--49)       66/66
   Successful extubation                                                                             62.1%          41/66
    Duration of mechanical ventilation, d, median (IQR)[^†^](#tblfn2){ref-type="table-fn"}     16.0 (10.0--21.0)       
   Tracheostomy                                                                                      21.2%          14/66
    Time to tracheostomy, d, median (IQR)                                                      22.5 (18.0--27.0)       
   Thrombotic event                                                                                  22.7%          15/66
   ICU discharge                                                                                     75.8%          50/66
    ICU length of stay, d, median (IQR)[^‡^](#tblfn3){ref-type="table-fn"}                     17.5 (13.0--25.0)       
   Death                                                                                             16.7%          11/66

*Definition of abbreviations*: ACEi = angiotensin-converting enzyme inhibitor; ARB = angiotensin receptor blocker; HD = hospital day; IQR = interquartile range.

Unless otherwise indicated.

Among patients who did not have tracheostomy placement.

Among patients who were discharged from the ICU.

Respiratory failure and respiratory system indices
--------------------------------------------------

Gas exchange and respiratory system mechanics are shown in [Figure 1](#fig1){ref-type="fig"}. On ICU admission, 56 patients (85%) met the Berlin criteria for ARDS, and most patients had mild-to-moderate ARDS ([@bib7]). On intubation, the median PEEP was 10 cm H~2~O (IQR, 8--12), plateau pressure was 21 cm H~2~O (IQR, 19--26), and driving pressure was 11 cm H~2~O (IQR, 9--12). The static compliance of the respiratory system was 35 ml/cm H~2~O (IQR, 30--43). The estimated physiologic dead-space ratio was 0.45 (IQR, 0.38--0.58).

![Respiratory indices during the first 5 days of mechanical ventilation. Respiratory indices, including the Pa~O~2~~:F[i]{.smallcaps}~O~2~~ ratio, plateau pressure (Pplat), positive end-expiratory pressure (PEEP), and static compliance of the respiratory system (Cstat~RS~), were obtained daily in intubated patients with coronavirus disease (COVID-19) respiratory failure. The number of patients with recorded values is shown below the *x*-axis. The solid line indicates the median value.](rccm.202004-1163LE_f1){#fig1}

Response to prone ventilation
-----------------------------

Among the 31 patients who underwent prone ventilation, the median Pa~O~2~~:F[i]{.smallcaps}~O~2~~ ratio in the supine position was 150 (IQR, 125--183) and compliance was 33 ml/cm H~2~O (IQR, 26--46 ml/cm H~2~O) immediately before prone positioning. After prone positioning, Pa~O~2~~:F[i]{.smallcaps}~O~2~~ increased to 232 (IQR, 174--304) and compliance increased to 36 ml/cm H~2~O (IQR, 33--44 ml/cm H~2~O). After the patients returned to the supine position, Pa~O~2~~:F[i]{.smallcaps}~O~2~~ was 217 (IQR, 149--263) and compliance was 35 ml/cm H~2~O (IQR, 31--41 ml/cm H~2~O). Seventy-two hours after initial prone ventilation, the patients had a Pa~O~2~~:F[i]{.smallcaps}~O~2~~ while supine of 233 (IQR, 167--265) and compliance of 42 ml/cm H~2~O (IQR, 34--47 ml/cm H~2~O). Over these 72 hours, the patients underwent prone ventilation for a median of two sessions (range, 1--3), with a median of 18 hours (IQR, 16--22 h) per session. Twelve patients (38.7%) received concurrent neuromuscular blockade. The median PEEP was 13 cm H~2~O (IQR, 12--15 cm H~2~O) while supine at all time points, and 14 cm H~2~O (IQR, 12--15 cm H~2~O) in the prone position.

Outcomes
--------

As of data censoring on April 28, 2020, the median patient follow-up was 34 days (range, 30--49 d; [Table 1](#tbl1){ref-type="table"}). Forty-one patients (62.1%) were successfully extubated, and among these patients the median duration of mechanical ventilation was 16.0 days (IQR, 10.0--21.0 d). Fourteen patients (21.2%) underwent tracheostomy. Fifty patients (75.8%) were discharged from the ICU. Eleven patients (16.7%) died.

Discussion
==========

We characterized COVID-19 respiratory failure in 66 patients managed with mechanical ventilation and established ARDS protocols. Almost all of the patients presented with dyspnea and were intubated on the day of hospital presentation. Upon initiation of mechanical ventilation, the patients had a median Pa~O~2~~:F[i]{.smallcaps}~O~2~~ of 182, dead-space fraction of 0.45, and compliance of 35 ml/cm H~2~O---findings that are consistent with previously described large cohorts of patients with ARDS ([@bib6], [@bib8], [@bib10]). The patients exhibited a spectrum of impaired gas exchange and respiratory system mechanics, and very few patients had near-normal compliance ([Figure 1](#fig1){ref-type="fig"}). Improvements in oxygenation and compliance with prone positioning were consistent with prior studies of prone ventilation in early ARDS ([@bib10]). Prone ventilation improves gas exchange in ARDS by increasing aerated areas of the lung, among other mechanisms ([@bib11]). Our findings thus differ from earlier series describing near-normal respiratory system compliance and a lack of recruitability in early presentations of COVID-19 respiratory failure ([@bib4], [@bib5]). The patients in our cohort were managed with established ARDS therapies, including low V[t]{.smallcaps} ventilation, conservative fluid administration, and, in many cases, prone ventilation. With a minimum follow-up of 30 days, overall mortality was 16.7% and the majority of the patients were successfully extubated and discharged from the ICU.

Our study has important limitations. The limited duration of patient follow-up in this retrospective study was driven by a focus on respiratory pathophysiology as opposed to clinical outcomes. Furthermore, it is possible that some patients were not intubated for reasons related to goals and preferences, and thus were not included in our cohort.

Patients with COVID-19 respiratory failure in our series exhibited gas exchange values, respiratory system mechanics, and responses to prone ventilation similar to those observed in large cohorts of patients with ARDS. Although further study is needed to elucidate the biology and unique features of this disease, our findings provide a pathophysiologic justification for the use of established ARDS therapies, including low V[t]{.smallcaps} and early prone ventilation, for COVID-19 respiratory failure.
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